Pending the results of the clinical trial, researchers are hoping that a transplant treatment using iPS cell-derived pancreatic cells will be available in the 2030s. The trial involves sheets of such pancreatic cells transplanted into three patients with severe Type 1 diabetes. The patients — between the ages of 20 and 65 — will also receive immunosuppressants and insulin treatments during the trial. The researchers will use iPS cell-derived pancreatic islet cells developed by Taro Toyoda, a lecturer at the university's Center for iPS Cell Research and Application (CiRA). Shinya Yamanaka, the founding director of CiRA, won a Nobel Prize in Physiology or Medicine in 2012 for his discovery of iPS cells, which are mature cells that can be reprogrammed to turn into any cell.